HBIO · Harvard Bioscience Inc · Metrics
$8.35
+0.03 (+0.36%)
At close · Oct 27
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$38.01M
Shares
4.55M
Volume · Oct 27
6053
Avg daily vol (3M)
18.42K
HBIO metrics
82 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$8.35
Market cap
$38.01M
Price action
20 metricsPrice change (1W)
+0.1%
Price change (30D)
+4.6%
Price change (3M)
+41.0%
Price change (6M)
+29.5%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
69.4%
Annualized volatility (3M)
36.7%
Beta
1.4
RSI (14D)
56.2
Price vs SMA 50
+4.0%
Price vs SMA 200
—
Avg volume (3M)
18,416
Relative volume
0.3
Average dollar volume
$140,045
Company
3 metricsSector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
4.55M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 129.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 231.8%
P / book
5.1
reciprocal yield 19.6%
FCF yield
-3.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
58.2
reciprocal yield 1.7%
Earnings yield
-27.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.1×
reciprocal yield 90.7%
EV / revenue historical average (5Y)
1.5×
reciprocal yield 68.0%
EV / EBIT historical average (3Y)
290.2×
reciprocal yield 0.3%
EV / EBIT historical average (5Y)
292.2×
reciprocal yield 0.3%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
2026-11-10
Last earnings
2026-08-11
Profitability
9 metricsGross margin
58.2%
Operating margin
-0.3%
Trailing 12 months
Net margin
-11.9%
Gross profit (TTM)
$51.07M
Operating profit (TTM)
−$245,000
Net income (TTM)
−$10.41M
Trailing 12 months
Diluted EPS (TTM)
$-2.27
FCF margin
-1.3%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+11.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$87.81M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.2%
Year over year · more shares
Revenue CAGR (3Y)
-8.6%
Revenue CAGR (5Y)
-3.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-7.7%
Quality
14 metricsReturn on equity
-140.4%
Return on assets
-13.6%
Debt / equity
4.9
Current ratio
1.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$1.12M
Quick ratio
1.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$30.18M
Latest balance sheet
Cash & equivalents
$6.50M
Total assets
$76.29M
Total debt
$36.68M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$651,000
Capital expenditures (TTM)
$1.77M
R&D (TTM)
$9.09M
SG&A (TTM)
—
Stock compensation (TTM)
$1.42M
R&D / revenue
10.4%
Stock compensation / revenue
1.6%
Ownership (13F)
9 metrics13F filers
37
13F filer change QoQ
0
Institutional ownership
36.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
20.5%
Private-fund adviser ownership
20.2%
Active holders' share change QoQ
+7.2%
Holder tenure
11.7
Price vs estimated holder cost
-10.7%
Ownership (registered funds)
1 metricsIndex-fund ownership
4.7%
Short interest
3 metricsShort interest
1.1%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
48 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—